Research

Hormonal

Liraglutide (1.8–3.0 mg) reduces ad libitum energy intake by approximately 16% and increases postprandial satiety in obese, non-diabetic adults, mediating weight loss through appetite suppression rather than increased energy expenditure.

For obese adults without diabetes, taking liraglutide (1.8 or 3.0 mg) once daily significantly reduces hunger and the amount of food eaten at meals (by about 16%) without needing to change exercise habits. This appetite suppression is the main reason for weight loss, not burning more calories. To minimize nausea, the dose should be started low and increased gradually.

GoodSupportsHIGH confidence
Liraglutide doses similarly increased mean postprandial satiety and fullness ratings, reduced hunger and prospective food consumption and decreased ad libitum energy intake by ~16%. Liraglutide-induced weight loss appears to be mediated by reduced appetite and energy intake rather than increased EE.
J van Can et al. · International Journal of Obesity · 2013

Why this rating

Randomized, double-blind, placebo-controlled crossover trial with objective metabolic chamber measurements.

Source

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

J van Can et al. · International Journal of Obesity · 2013

DOI 10.1038/ijo.2013.162

crossover · n=49Cited 514×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →